In this prospective trial, addition of a biofilm disrupting antimicrobial agent to NPWT reduced surface area and led to improved wound healing in 4/6 recalcitrant pressure ulcers
A reduction in wound area correlated with a reduction in bacterial burden as evidenced by fluorescence imaging (MolecuLight i:X)
The MolecuLight procedure enabled detection of bacteria build up in the NPWT sponges at the point-of-care
This study aimed to assess the efficacy and safety of a porcine peritoneum-derived matrix, a type of cellular and/or tissue product for treatment of DFUs
MolecuLight i:X imaging and measurement of bacterial protease activity (BPA) were performed weekly to evaluate bacterial load in wounds
Low bacterial loads, indicated by absence of fluorescence on MolecuLight i:X images and negative BPA, predicted wound healing
Fluorescence imaging was used to inform on the presence of bacterial loads in stage 3 and 4 pressure ulcers
These pressure ulcers underwent NPWT and treatment with a biofilm disrupting agent
In wounds where negative fluorescence images suggested lower bacterial levels, a reduction in wound surface area and volume was observed
This RCT used fluorescence imaging to evaluate the effects of cold atmospheric plasma on wound area of chronic wounds
Fluorescence images were used to visualize the bacterially colonized area and compare the area before and after
50.4 % reduction of bacterial load for Group 1 and 35.0 % for Group 2 compared to the day of study
MolecuLight i:X
is designated as a
MolecuLight is a proud corporate member of:
© 2021
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.